Skip to main content
. 2021 Jun 14;188(2):369–377. doi: 10.1007/s10549-021-06197-5

Table 2.

TEAEs in patients who continued on monotherapy (≥ 5% in Either Treatment Group)

TEAEs, n (%) Patients, n (%)
Trastuzumab-dkst (N = 179) Trastuzumab (N = 164)
All grades Grade ≥ 3 All grades Grade ≥ 3
Any TEAE 124 (69.3) 23 (12.8) 119 (72.6) 31 (18.9)
Headache 19 (10.6) 0 23 (14.0) 4 (2.4)
Hypertension 12 (6.7) 2 (1.1) 9 (5.5) 1 (0.6)
Increased ALT 11 (6.1) 2 (1.1) 7 (4.3) 3 (1.8)
Vomiting 10 (5.6) 0 7 (4.3) 0
Decreased ejection fraction 10 (5.6) 0 6 (3.7) 1 (0.6)
Upper respiratory tract infection 10 (5.6) 0 4 (2.4) 0
Increased AST 9 (5.0) 1 (0.6) 7 (4.3) 3 (1.8)
Fatigue 9 (5.0) 0 7 (4.3) 0
Arthralgia 9 (5.0) 0 3 (1.8) 0
Cough 9 (5.0) 0 3 (1.8) 0
Anemia 6 (3.4) 0 17 (10.4) 2 (1.2)
Peripheral neuropathy 5 (2.8) 0 9 (5.5) 0

ALT alanine aminotransferase, AST aspartate aminotransferase